pour la recherche uniquement
Réf. Catalogue: S1579
| Lignées cellulaires | Type d'essai | Concentration | Temps d'incubation | Formulation | Description de l'activité | PMID |
|---|---|---|---|---|---|---|
| H157 | Growth Inhibition Assay | 0-100 μM | 72 h | IC50=9 μM | 26390342 | |
| H2170 | Growth Inhibition Assay | 0-100 μM | 72 h | IC50=5 μM | 26390342 | |
| H520 | Growth Inhibition Assay | 0-100 μM | 72 h | IC50=0.73 μM | 26390342 | |
| H596 | Growth Inhibition Assay | 0-100 μM | 72 h | IC50=12 μM | 26390342 | |
| IMR-32 | Growth Inhibition Assay | 48 h | DMSO | IC50=261 nM | 26225123 | |
| SH-SY5Y | Growth Inhibition Assay | 48 h | DMSO | IC50=676 nM | 26225123 | |
| NGP | Growth Inhibition Assay | 48 h | DMSO | IC50=2.077 μM | 26225123 | |
| SH-EP | Growth Inhibition Assay | 48 h | DMSO | IC50=2.211 μM | 26225123 | |
| IMR-32 | Growth Inhibition Assay | 1 μM | 24 h | DMSO | induces G1 arrest | 26225123 |
| SH-SY5Y | Growth Inhibition Assay | 1 μM | 24 h | DMSO | induces G1 arrest | 26225123 |
| NGP | Growth Inhibition Assay | 1 μM | 24 h | DMSO | induces G1 arrest | 26225123 |
| SH-EP | Growth Inhibition Assay | 1 μM | 24 h | DMSO | induces G1 arrest | 26225123 |
| NGP | Fuction Assay | 0-1 μM | 24 h | DMSO | reduces the expression of TOP2A, CCNE2, and TK1 in a dose-dependent manner | 26225123 |
| IMR-32 | Fuction Assay | 0-1 μM | 24 h | DMSO | reduces the expression of TOP2A, CCNE2, and TK1 in a dose-dependent manner | 26225123 |
| U-CH2 | Growth Inhibition Assay | 0-1 μM | 72 h | IC50=50.2 nM | 26183925 | |
| U-CH3 | Growth Inhibition Assay | 0-1 μM | 72 h | IC50=52 nM | 26183925 | |
| U-CH6 | Growth Inhibition Assay | 0-1 μM | 72 h | IC50=90 nM | 26183925 | |
| U-CH7 | Growth Inhibition Assay | 0-1 μM | 72 h | IC50=98 nM | 26183925 | |
| U-CH11 | Growth Inhibition Assay | 0-1 μM | 72 h | IC50=340 nM | 26183925 | |
| MCF7 | Fuction Assay | 2.5-250 nM | 24 h | reduces Rb phosphorylation | 25991817 | |
| MV4-11 | Apoptosis Assay | 0.5 μM | 24 h | enhances apoptosis induced by sorafenib and AC220 | 25487917 | |
| MOLM13 | Apoptosis Assay | 0.5 μM | 24 h | enhances apoptosis induced by sorafenib and AC220 | 25487917 | |
| MOLM13-ITD alone | Growth Inhibition Assay | IC50=0.089 ± 0.009 μM | 25487917 | |||
| MV4-11-ITD alone | Growth Inhibition Assay | IC50=0.092 ± 0.008 μM | 25487917 | |||
| MOLM13-ITD/D835Y | Growth Inhibition Assay | IC50=0.114 ± 0.011 μM | 25487917 | |||
| MV4-11-ITD/D835V | Growth Inhibition Assay | IC50=0.116 ± 0.011 μM | 25487917 | |||
| MV4-11-ITD/D835V | Growth Inhibition Assay | IC50=0.102 ± 0.006 μM | 25487917 | |||
| MV4-11-ITD/F691L | Growth Inhibition Assay | IC50=0.112 ± 0.015 μM | 25487917 | |||
| MV4-11-ITD/N841K | Growth Inhibition Assay | IC50=0.113 ± 0.002 μM | 25487917 | |||
| U937-FLT3 WT | Growth Inhibition Assay | IC50=0.102 ± 0.013 μM | 25487917 | |||
| P12-ICHIKAWA | Growth Inhibition assay | IC50 = 0.09604 μM | SANGER | |||
| 697 | Growth Inhibition assay | IC50 = 0.14838 μM | SANGER | |||
| NB69 | Growth Inhibition assay | IC50 = 0.1618 μM | SANGER | |||
| EoL-1-cell | Growth Inhibition assay | IC50 = 0.18726 μM | SANGER | |||
| BHT-101 | Growth Inhibition assay | IC50 = 0.19825 μM | SANGER | |||
| SK-NEP-1 | Growth Inhibition assay | IC50 = 0.22002 μM | SANGER | |||
| MHH-NB-11 | Growth Inhibition assay | IC50 = 0.22019 μM | SANGER | |||
| AsPC-1 | Growth Inhibition assay | IC50 = 0.25253 μM | SANGER | |||
| ES1 | Growth Inhibition assay | IC50 = 0.25625 μM | SANGER | |||
| LAMA-84 | Growth Inhibition assay | IC50 = 0.25819 μM | SANGER | |||
| MOLT-16 | Growth Inhibition assay | IC50 = 0.25849 μM | SANGER | |||
| ES7 | Growth Inhibition assay | IC50 = 0.27309 μM | SANGER | |||
| KY821 | Growth Inhibition assay | IC50 = 0.3141 μM | SANGER | |||
| RT-112 | Growth Inhibition assay | IC50 = 0.32105 μM | SANGER | |||
| HL-60 | Growth Inhibition assay | IC50 = 0.34066 μM | SANGER | |||
| MOLT-4 | Growth Inhibition assay | IC50 = 0.34513 μM | SANGER | |||
| KARPAS-45 | Growth Inhibition assay | IC50 = 0.37616 μM | SANGER | |||
| SK-N-AS | Growth Inhibition assay | IC50 = 0.38783 μM | SANGER | |||
| CTB-1 | Growth Inhibition assay | IC50 = 0.40502 μM | SANGER | |||
| NKM-1 | Growth Inhibition assay | IC50 = 0.41189 μM | SANGER | |||
| HTC-C3 | Growth Inhibition assay | IC50 = 0.43295 μM | SANGER | |||
| BE-13 | Growth Inhibition assay | IC50 = 0.44427 μM | SANGER | |||
| KOSC-2 | Growth Inhibition assay | IC50 = 0.4669 μM | SANGER | |||
| NB14 | Growth Inhibition assay | IC50 = 0.48358 μM | SANGER | |||
| CAL-27 | Growth Inhibition assay | IC50 = 0.49459 μM | SANGER | |||
| H9 | Growth Inhibition assay | IC50 = 0.49543 μM | SANGER | |||
| RS4-11 | Growth Inhibition assay | IC50 = 0.50473 μM | SANGER | |||
| PA-1 | Growth Inhibition assay | IC50 = 0.50986 μM | SANGER | |||
| MV-4-11 | Growth Inhibition assay | IC50 = 0.51385 μM | SANGER | |||
| OS-RC-2 | Growth Inhibition assay | IC50 = 0.52162 μM | SANGER | |||
| RPMI-8226 | Growth Inhibition assay | IC50 = 0.52686 μM | SANGER | |||
| HGC-27 | Growth Inhibition assay | IC50 = 0.56499 μM | SANGER | |||
| CHP-212 | Growth Inhibition assay | IC50 = 0.59359 μM | SANGER | |||
| NB10 | Growth Inhibition assay | IC50 = 0.59918 μM | SANGER | |||
| HH | Growth Inhibition assay | IC50 = 0.59943 μM | SANGER | |||
| EW-16 | Growth Inhibition assay | IC50 = 0.60352 μM | SANGER | |||
| ES8 | Growth Inhibition assay | IC50 = 0.60521 μM | SANGER | |||
| HAL-01 | Growth Inhibition assay | IC50 = 0.60567 μM | SANGER | |||
| A204 | Growth Inhibition assay | IC50 = 0.63391 μM | SANGER | |||
| MHH-PREB-1 | Growth Inhibition assay | IC50 = 0.63699 μM | SANGER | |||
| EM-2 | Growth Inhibition assay | IC50 = 0.65064 μM | SANGER | |||
| BV-173 | Growth Inhibition assay | IC50 = 0.65248 μM | SANGER | |||
| ONS-76 | Growth Inhibition assay | IC50 = 0.67782 μM | SANGER | |||
| KM-H2 | Growth Inhibition assay | IC50 = 0.69554 μM | SANGER | |||
| D-263MG | Growth Inhibition assay | IC50 = 0.71712 μM | SANGER | |||
| ES3 | Growth Inhibition assay | IC50 = 0.72893 μM | SANGER | |||
| VA-ES-BJ | Growth Inhibition assay | IC50 = 0.73227 μM | SANGER | |||
| NBsusSR | Growth Inhibition assay | IC50 = 0.74299 μM | SANGER | |||
| NCI-H520 | Growth Inhibition assay | IC50 = 0.74652 μM | SANGER | |||
| ES5 | Growth Inhibition assay | IC50 = 0.7528 μM | SANGER | |||
| T-24 | Growth Inhibition assay | IC50 = 0.77871 μM | SANGER | |||
| SW962 | Growth Inhibition assay | IC50 = 0.80863 μM | SANGER | |||
| EW-3 | Growth Inhibition assay | IC50 = 0.80876 μM | SANGER | |||
| RXF393 | Growth Inhibition assay | IC50 = 0.81279 μM | SANGER | |||
| U251 | Growth Inhibition assay | IC50 = 0.81388 μM | SANGER | |||
| CAMA-1 | Growth Inhibition assay | IC50 = 0.83394 μM | SANGER | |||
| JVM-3 | Growth Inhibition assay | IC50 = 0.85178 μM | SANGER | |||
| COLO-800 | Growth Inhibition assay | IC50 = 0.89778 μM | SANGER | |||
| OVCAR-5 | Growth Inhibition assay | IC50 = 0.9001 μM | SANGER | |||
| LB1047-RCC | Growth Inhibition assay | IC50 = 0.92756 μM | SANGER | |||
| SW954 | Growth Inhibition assay | IC50 = 0.92941 μM | SANGER | |||
| J-RT3-T3-5 | Growth Inhibition assay | IC50 = 0.93606 μM | SANGER | |||
| Mewo | Growth Inhibition assay | IC50 = 0.9366 μM | SANGER | |||
| NCI-H1770 | Growth Inhibition assay | IC50 = 0.94055 μM | SANGER | |||
| HO-1-N-1 | Growth Inhibition assay | IC50 = 0.96281 μM | SANGER | |||
| HSC-3 | Growth Inhibition assay | IC50 = 0.96648 μM | SANGER | |||
| TYK-nu | Growth Inhibition assay | IC50 = 0.99825 μM | SANGER | |||
| KYSE-150 | Growth Inhibition assay | IC50 = 1.00076 μM | SANGER | |||
| SN12C | Growth Inhibition assay | IC50 = 1.00875 μM | SANGER | |||
| MOLT-13 | Growth Inhibition assay | IC50 = 1.01421 μM | SANGER | |||
| TE-11 | Growth Inhibition assay | IC50 = 1.04812 μM | SANGER | |||
| DB | Growth Inhibition assay | IC50 = 1.07273 μM | SANGER | |||
| CAL-39 | Growth Inhibition assay | IC50 = 1.07522 μM | SANGER | |||
| A3-KAW | Growth Inhibition assay | IC50 = 1.08408 μM | SANGER | |||
| CHP-134 | Growth Inhibition assay | IC50 = 1.11807 μM | SANGER | |||
| TGW | Growth Inhibition assay | IC50 = 1.12395 μM | SANGER | |||
| QIMR-WIL | Growth Inhibition assay | IC50 = 1.13134 μM | SANGER | |||
| NCI-SNU-1 | Growth Inhibition assay | IC50 = 1.16354 μM | SANGER | |||
| CGTH-W-1 | Growth Inhibition assay | IC50 = 1.17186 μM | SANGER | |||
| MHH-ES-1 | Growth Inhibition assay | IC50 = 1.17986 μM | SANGER | |||
| LB2241-RCC | Growth Inhibition assay | IC50 = 1.1862 μM | SANGER | |||
| ML-2 | Growth Inhibition assay | IC50 = 1.20734 μM | SANGER | |||
| COR-L23 | Growth Inhibition assay | IC50 = 1.22933 μM | SANGER | |||
| BFTC-905 | Growth Inhibition assay | IC50 = 1.24267 μM | SANGER | |||
| Hs-578-T | Growth Inhibition assay | IC50 = 1.25817 μM | SANGER | |||
| KG-1 | Growth Inhibition assay | IC50 = 1.26686 μM | SANGER | |||
| HEL | Growth Inhibition assay | IC50 = 1.29338 μM | SANGER | |||
| A549 | Growth Inhibition assay | IC50 = 1.29399 μM | SANGER | |||
| COLO-741 | Growth Inhibition assay | IC50 = 1.32089 μM | SANGER | |||
| PC-3 | Growth Inhibition assay | IC50 = 1.35221 μM | SANGER | |||
| HOS | Growth Inhibition assay | IC50 = 1.35296 μM | SANGER | |||
| HT-1080 | Growth Inhibition assay | IC50 = 1.37519 μM | SANGER | |||
| TE-8 | Growth Inhibition assay | IC50 = 1.41774 μM | SANGER | |||
| BHY | Growth Inhibition assay | IC50 = 1.46923 μM | SANGER | |||
| BB65-RCC | Growth Inhibition assay | IC50 = 1.50528 μM | SANGER | |||
| HN | Growth Inhibition assay | IC50 = 1.54071 μM | SANGER | |||
| NCI-H441 | Growth Inhibition assay | IC50 = 1.54907 μM | SANGER | |||
| RPMI-8866 | Growth Inhibition assay | IC50 = 1.58507 μM | SANGER | |||
| CAL-62 | Growth Inhibition assay | IC50 = 1.60862 μM | SANGER | |||
| MG-63 | Growth Inhibition assay | IC50 = 1.61813 μM | SANGER | |||
| SK-LU-1 | Growth Inhibition assay | IC50 = 1.62152 μM | SANGER | |||
| BCPAP | Growth Inhibition assay | IC50 = 1.66457 μM | SANGER | |||
| 22RV1 | Growth Inhibition assay | IC50 = 1.67843 μM | SANGER | |||
| T47D | Growth Inhibition assay | IC50 = 1.68061 μM | SANGER | |||
| MSTO-211H | Growth Inhibition assay | IC50 = 1.69603 μM | SANGER | |||
| DEL | Growth Inhibition assay | IC50 = 1.70273 μM | SANGER | |||
| H4 | Growth Inhibition assay | IC50 = 1.73212 μM | SANGER | |||
| CAL-51 | Growth Inhibition assay | IC50 = 1.74855 μM | SANGER | |||
| ABC-1 | Growth Inhibition assay | IC50 = 1.78582 μM | SANGER | |||
| MZ2-MEL | Growth Inhibition assay | IC50 = 1.79542 μM | SANGER | |||
| YKG-1 | Growth Inhibition assay | IC50 = 1.81061 μM | SANGER | |||
| KM12 | Growth Inhibition assay | IC50 = 1.81602 μM | SANGER | |||
| L-363 | Growth Inhibition assay | IC50 = 1.87412 μM | SANGER | |||
| KU812 | Growth Inhibition assay | IC50 = 1.89282 μM | SANGER | |||
| LOXIMVI | Growth Inhibition assay | IC50 = 1.91228 μM | SANGER | |||
| G-401 | Growth Inhibition assay | IC50 = 1.92428 μM | SANGER | |||
| SW780 | Growth Inhibition assay | IC50 = 1.96246 μM | SANGER | |||
| SW872 | Growth Inhibition assay | IC50 = 1.9833 μM | SANGER | |||
| NB7 | Growth Inhibition assay | IC50 = 1.99323 μM | SANGER | |||
| T98G | Growth Inhibition assay | IC50 = 2.00666 μM | SANGER | |||
| SW1710 | Growth Inhibition assay | IC50 = 2.06945 μM | SANGER | |||
| NCI-H1573 | Growth Inhibition assay | IC50 = 2.07298 μM | SANGER | |||
| KE-37 | Growth Inhibition assay | IC50 = 2.08951 μM | SANGER | |||
| 786-0 | Growth Inhibition assay | IC50 = 2.15439 μM | SANGER | |||
| SAS | Growth Inhibition assay | IC50 = 2.20374 μM | SANGER | |||
| CAL-54 | Growth Inhibition assay | IC50 = 2.20413 μM | SANGER | |||
| SF268 | Growth Inhibition assay | IC50 = 2.23122 μM | SANGER | |||
| SW620 | Growth Inhibition assay | IC50 = 2.26169 μM | SANGER | |||
| MN-60 | Growth Inhibition assay | IC50 = 2.3106 μM | SANGER | |||
| EFO-27 | Growth Inhibition assay | IC50 = 2.32058 μM | SANGER | |||
| NCI-H747 | Growth Inhibition assay | IC50 = 2.32199 μM | SANGER | |||
| HCC2218 | Growth Inhibition assay | IC50 = 2.35374 μM | SANGER | |||
| MIA-PaCa-2 | Growth Inhibition assay | IC50 = 2.36437 μM | SANGER | |||
| SJSA-1 | Growth Inhibition assay | IC50 = 2.37796 μM | SANGER | |||
| RKO | Growth Inhibition assay | IC50 = 2.38496 μM | SANGER | |||
| NB6 | Growth Inhibition assay | IC50 = 2.40374 μM | SANGER | |||
| ES4 | Growth Inhibition assay | IC50 = 2.45422 μM | SANGER | |||
| EGI-1 | Growth Inhibition assay | IC50 = 2.46883 μM | SANGER | |||
| CTV-1 | Growth Inhibition assay | IC50 = 2.52773 μM | SANGER | |||
| NCI-H1355 | Growth Inhibition assay | IC50 = 2.55951 μM | SANGER | |||
| GT3TKB | Growth Inhibition assay | IC50 = 2.59199 μM | SANGER | |||
| SK-HEP-1 | Growth Inhibition assay | IC50 = 2.59266 μM | SANGER | |||
| GAMG | Growth Inhibition assay | IC50 = 2.59394 μM | SANGER | |||
| SK-MES-1 | Growth Inhibition assay | IC50 = 2.61803 μM | SANGER | |||
| RO82-W-1 | Growth Inhibition assay | IC50 = 2.62057 μM | SANGER | |||
| ECC10 | Growth Inhibition assay | IC50 = 2.70206 μM | SANGER | |||
| MCF7 | Growth Inhibition assay | IC50 = 2.71464 μM | SANGER | |||
| D-283MED | Growth Inhibition assay | IC50 = 2.7243 μM | SANGER | |||
| RPMI-7951 | Growth Inhibition assay | IC50 = 2.75694 μM | SANGER | |||
| Ramos-2G6-4C10 | Growth Inhibition assay | IC50 = 2.77099 μM | SANGER | |||
| KGN | Growth Inhibition assay | IC50 = 2.81884 μM | SANGER | |||
| NUGC-3 | Growth Inhibition assay | IC50 = 2.82505 μM | SANGER | |||
| NCI-H292 | Growth Inhibition assay | IC50 = 2.85053 μM | SANGER | |||
| Becker | Growth Inhibition assay | IC50 = 2.95832 μM | SANGER | |||
| NCI-H1299 | Growth Inhibition assay | IC50 = 3.05263 μM | SANGER | |||
| ETK-1 | Growth Inhibition assay | IC50 = 3.0543 μM | SANGER | |||
| TK10 | Growth Inhibition assay | IC50 = 3.20165 μM | SANGER | |||
| VMRC-RCZ | Growth Inhibition assay | IC50 = 3.36488 μM | SANGER | |||
| YH-13 | Growth Inhibition assay | IC50 = 3.44079 μM | SANGER | |||
| DU-145 | Growth Inhibition assay | IC50 = 3.46269 μM | SANGER | |||
| SW1088 | Growth Inhibition assay | IC50 = 3.4747 μM | SANGER | |||
| HOP-92 | Growth Inhibition assay | IC50 = 3.50342 μM | SANGER | |||
| KP-N-YS | Growth Inhibition assay | IC50 = 3.62139 μM | SANGER | |||
| NCI-H460 | Growth Inhibition assay | IC50 = 3.6673 μM | SANGER | |||
| U-2-OS | Growth Inhibition assay | IC50 = 3.72535 μM | SANGER | |||
| A101D | Growth Inhibition assay | IC50 = 3.76936 μM | SANGER | |||
| MDA-MB-231 | Growth Inhibition assay | IC50 = 3.81951 μM | SANGER | |||
| IST-MES1 | Growth Inhibition assay | IC50 = 3.832 μM | SANGER | |||
| COR-L105 | Growth Inhibition assay | IC50 = 4.018 μM | SANGER | |||
| NCI-H1437 | Growth Inhibition assay | IC50 = 4.02302 μM | SANGER | |||
| CAL-85-1 | Growth Inhibition assay | IC50 = 4.02461 μM | SANGER | |||
| MZ1-PC | Growth Inhibition assay | IC50 = 4.18556 μM | SANGER | |||
| VM-CUB-1 | Growth Inhibition assay | IC50 = 4.31284 μM | SANGER | |||
| CHL-1 | Growth Inhibition assay | IC50 = 4.32169 μM | SANGER | |||
| MDA-MB-361 | Growth Inhibition assay | IC50 = 4.33153 μM | SANGER | |||
| NCI-H661 | Growth Inhibition assay | IC50 = 4.50092 μM | SANGER | |||
| EW-11 | Growth Inhibition assay | IC50 = 4.52231 μM | SANGER | |||
| BEN | Growth Inhibition assay | IC50 = 4.52815 μM | SANGER | |||
| BFTC-909 | Growth Inhibition assay | IC50 = 4.56275 μM | SANGER | |||
| NCI-H2087 | Growth Inhibition assay | IC50 = 4.58164 μM | SANGER | |||
| RVH-421 | Growth Inhibition assay | IC50 = 4.6669 μM | SANGER | |||
| P30-OHK | Growth Inhibition assay | IC50 = 4.68008 μM | SANGER | |||
| NCI-H28 | Growth Inhibition assay | IC50 = 4.81661 μM | SANGER | |||
| ES6 | Growth Inhibition assay | IC50 = 4.83016 μM | SANGER | |||
| 769-P | Growth Inhibition assay | IC50 = 4.85926 μM | SANGER | |||
| OE33 | Growth Inhibition assay | IC50 = 4.88161 μM | SANGER | |||
| SW982 | Growth Inhibition assay | IC50 = 4.95061 μM | SANGER | |||
| A388 | Growth Inhibition assay | IC50 = 5.02983 μM | SANGER | |||
| TI-73 | Growth Inhibition assay | IC50 = 5.06194 μM | SANGER | |||
| HCT-116 | Growth Inhibition assay | IC50 = 5.09889 μM | SANGER | |||
| HuP-T3 | Growth Inhibition assay | IC50 = 5.18709 μM | SANGER | |||
| G-402 | Growth Inhibition assay | IC50 = 5.19416 μM | SANGER | |||
| NCI-H1792 | Growth Inhibition assay | IC50 = 5.24622 μM | SANGER | |||
| NCI-H209 | Growth Inhibition assay | IC50 = 5.25942 μM | SANGER | |||
| NCI-H1650 | Growth Inhibition assay | IC50 = 5.30634 μM | SANGER | |||
| LCLC-97TM1 | Growth Inhibition assay | IC50 = 5.31808 μM | SANGER | |||
| S-117 | Growth Inhibition assay | IC50 = 5.36976 μM | SANGER | |||
| GI-ME-N | Growth Inhibition assay | IC50 = 5.39681 μM | SANGER | |||
| NCI-H2122 | Growth Inhibition assay | IC50 = 5.49397 μM | SANGER | |||
| NCI-H1793 | Growth Inhibition assay | IC50 = 5.67593 μM | SANGER | |||
| C2BBe1 | Growth Inhibition assay | IC50 = 5.70088 μM | SANGER | |||
| TE-12 | Growth Inhibition assay | IC50 = 5.80556 μM | SANGER | |||
| LCLC-103H | Growth Inhibition assay | IC50 = 5.917 μM | SANGER | |||
| A673 | Growth Inhibition assay | IC50 = 5.91932 μM | SANGER | |||
| BB30-HNC | Growth Inhibition assay | IC50 = 5.9836 μM | SANGER | |||
| SF295 | Growth Inhibition assay | IC50 = 6.00422 μM | SANGER | |||
| KU-19-19 | Growth Inhibition assay | IC50 = 6.01731 μM | SANGER | |||
| CFPAC-1 | Growth Inhibition assay | IC50 = 6.04443 μM | SANGER | |||
| LoVo | Growth Inhibition assay | IC50 = 6.05063 μM | SANGER | |||
| 8505C | Growth Inhibition assay | IC50 = 6.07573 μM | SANGER | |||
| GMS-10 | Growth Inhibition assay | IC50 = 6.15002 μM | SANGER | |||
| Ca9-22 | Growth Inhibition assay | IC50 = 6.1671 μM | SANGER | |||
| DOK | Growth Inhibition assay | IC50 = 6.22072 μM | SANGER | |||
| FADU | Growth Inhibition assay | IC50 = 6.26039 μM | SANGER | |||
| BxPC-3 | Growth Inhibition assay | IC50 = 6.2732 μM | SANGER | |||
| CAL-33 | Growth Inhibition assay | IC50 = 6.29201 μM | SANGER | |||
| SHP-77 | Growth Inhibition assay | IC50 = 6.31512 μM | SANGER | |||
| LXF-289 | Growth Inhibition assay | IC50 = 6.33455 μM | SANGER | |||
| GB-1 | Growth Inhibition assay | IC50 = 6.382 μM | SANGER | |||
| KS-1 | Growth Inhibition assay | IC50 = 6.38447 μM | SANGER | |||
| D-502MG | Growth Inhibition assay | IC50 = 6.42376 μM | SANGER | |||
| LAN-6 | Growth Inhibition assay | IC50 = 6.51023 μM | SANGER | |||
| H-EMC-SS | Growth Inhibition assay | IC50 = 6.56147 μM | SANGER | |||
| LC-2-ad | Growth Inhibition assay | IC50 = 6.60076 μM | SANGER | |||
| NCI-H1693 | Growth Inhibition assay | IC50 = 6.62215 μM | SANGER | |||
| SK-N-FI | Growth Inhibition assay | IC50 = 6.75044 μM | SANGER | |||
| D-423MG | Growth Inhibition assay | IC50 = 6.76117 μM | SANGER | |||
| KNS-42 | Growth Inhibition assay | IC50 = 6.78197 μM | SANGER | |||
| GCT | Growth Inhibition assay | IC50 = 6.938 μM | SANGER | |||
| DSH1 | Growth Inhibition assay | IC50 = 7.0633 μM | SANGER | |||
| D-247MG | Growth Inhibition assay | IC50 = 7.07881 μM | SANGER | |||
| NCI-SNU-5 | Growth Inhibition assay | IC50 = 7.18371 μM | SANGER | |||
| TE-6 | Growth Inhibition assay | IC50 = 7.20601 μM | SANGER | |||
| NOMO-1 | Growth Inhibition assay | IC50 = 7.22127 μM | SANGER | |||
| NB17 | Growth Inhibition assay | IC50 = 7.30309 μM | SANGER | |||
| EW-22 | Growth Inhibition assay | IC50 = 7.34348 μM | SANGER | |||
| EW-13 | Growth Inhibition assay | IC50 = 7.35162 μM | SANGER | |||
| DOHH-2 | Growth Inhibition assay | IC50 = 7.4402 μM | SANGER | |||
| TGBC1TKB | Growth Inhibition assay | IC50 = 7.49899 μM | SANGER | |||
| GR-ST | Growth Inhibition assay | IC50 = 7.52594 μM | SANGER | |||
| KYSE-520 | Growth Inhibition assay | IC50 = 7.55515 μM | SANGER | |||
| CAPAN-1 | Growth Inhibition assay | IC50 = 7.5951 μM | SANGER | |||
| HCE-4 | Growth Inhibition assay | IC50 = 7.62279 μM | SANGER | |||
| MLMA | Growth Inhibition assay | IC50 = 7.62957 μM | SANGER | |||
| HT-144 | Growth Inhibition assay | IC50 = 7.65368 μM | SANGER | |||
| KYSE-180 | Growth Inhibition assay | IC50 = 7.71169 μM | SANGER | |||
| TE-5 | Growth Inhibition assay | IC50 = 7.95971 μM | SANGER | |||
| IGROV-1 | Growth Inhibition assay | IC50 = 7.98551 μM | SANGER | |||
| NCI-H1581 | Growth Inhibition assay | IC50 = 8.012 μM | SANGER | |||
| SW1990 | Growth Inhibition assay | IC50 = 8.04659 μM | SANGER | |||
| EFM-19 | Growth Inhibition assay | IC50 = 8.08545 μM | SANGER | |||
| IGR-1 | Growth Inhibition assay | IC50 = 8.43023 μM | SANGER | |||
| U-118-MG | Growth Inhibition assay | IC50 = 8.43463 μM | SANGER | |||
| SK-OV-3 | Growth Inhibition assay | IC50 = 8.46765 μM | SANGER | |||
| KNS-62 | Growth Inhibition assay | IC50 = 8.51761 μM | SANGER | |||
| GOTO | Growth Inhibition assay | IC50 = 8.57635 μM | SANGER | |||
| 8305C | Growth Inhibition assay | IC50 = 8.70484 μM | SANGER | |||
| RPMI-2650 | Growth Inhibition assay | IC50 = 8.71955 μM | SANGER | |||
| NEC8 | Growth Inhibition assay | IC50 = 8.74307 μM | SANGER | |||
| KYSE-450 | Growth Inhibition assay | IC50 = 8.86548 μM | SANGER | |||
| RMG-I | Growth Inhibition assay | IC50 = 9.14058 μM | SANGER | |||
| CAKI-1 | Growth Inhibition assay | IC50 = 9.31979 μM | SANGER | |||
| KYSE-510 | Growth Inhibition assay | IC50 = 9.35778 μM | SANGER | |||
| A4-Fuk | Growth Inhibition assay | IC50 = 9.36701 μM | SANGER | |||
| AN3-CA | Growth Inhibition assay | IC50 = 9.45444 μM | SANGER | |||
| SK-N-DZ | Growth Inhibition assay | IC50 = 9.72849 μM | SANGER | |||
| HSC-2 | Growth Inhibition assay | IC50 = 9.76629 μM | SANGER | |||
| EW-1 | Growth Inhibition assay | IC50 = 9.79369 μM | SANGER | |||
| D-566MG | Growth Inhibition assay | IC50 = 9.83664 μM | SANGER | |||
| COLO-792 | Growth Inhibition assay | IC50 = 9.98746 μM | SANGER | |||
| TE-10 | Growth Inhibition assay | IC50 = 10.0396 μM | SANGER | |||
| NCI-H650 | Growth Inhibition assay | IC50 = 10.4286 μM | SANGER | |||
| U-266 | Growth Inhibition assay | IC50 = 10.455 μM | SANGER | |||
| Detroit562 | Growth Inhibition assay | IC50 = 11.0515 μM | SANGER | |||
| NH-12 | Growth Inhibition assay | IC50 = 11.1446 μM | SANGER | |||
| OC-314 | Growth Inhibition assay | IC50 = 11.2842 μM | SANGER | |||
| IST-MEL1 | Growth Inhibition assay | IC50 = 11.5323 μM | SANGER | |||
| KNS-81-FD | Growth Inhibition assay | IC50 = 11.5527 μM | SANGER | |||
| SW1463 | Growth Inhibition assay | IC50 = 11.5989 μM | SANGER | |||
| NCI-H23 | Growth Inhibition assay | IC50 = 11.6553 μM | SANGER | |||
| SK-MEL-2 | Growth Inhibition assay | IC50 = 11.7197 μM | SANGER | |||
| NB13 | Growth Inhibition assay | IC50 = 12.1495 μM | SANGER | |||
| Daoy | Growth Inhibition assay | IC50 = 12.2855 μM | SANGER | |||
| NCI-H1623 | Growth Inhibition assay | IC50 = 12.3801 μM | SANGER | |||
| NMC-G1 | Growth Inhibition assay | IC50 = 12.717 μM | SANGER | |||
| DK-MG | Growth Inhibition assay | IC50 = 12.9482 μM | SANGER | |||
| TCCSUP | Growth Inhibition assay | IC50 = 13.1284 μM | SANGER | |||
| SCC-15 | Growth Inhibition assay | IC50 = 13.2651 μM | SANGER | |||
| NOS-1 | Growth Inhibition assay | IC50 = 13.2893 μM | SANGER | |||
| RH-1 | Growth Inhibition assay | IC50 = 13.3037 μM | SANGER | |||
| SK-MEL-3 | Growth Inhibition assay | IC50 = 13.3728 μM | SANGER | |||
| NB5 | Growth Inhibition assay | IC50 = 13.4067 μM | SANGER | |||
| SNU-387 | Growth Inhibition assay | IC50 = 13.5072 μM | SANGER | |||
| CAL-120 | Growth Inhibition assay | IC50 = 13.6718 μM | SANGER | |||
| LNCaP-Clone-FGC | Growth Inhibition assay | IC50 = 13.7991 μM | SANGER | |||
| ACN | Growth Inhibition assay | IC50 = 14.0288 μM | SANGER | |||
| SK-MEL-30 | Growth Inhibition assay | IC50 = 14.063 μM | SANGER | |||
| COLO-678 | Growth Inhibition assay | IC50 = 14.0822 μM | SANGER | |||
| SCC-9 | Growth Inhibition assay | IC50 = 14.1021 μM | SANGER | |||
| KINGS-1 | Growth Inhibition assay | IC50 = 14.1402 μM | SANGER | |||
| LS-513 | Growth Inhibition assay | IC50 = 14.187 μM | SANGER | |||
| HLE | Growth Inhibition assay | IC50 = 14.3852 μM | SANGER | |||
| SW1573 | Growth Inhibition assay | IC50 = 14.4435 μM | SANGER | |||
| KYSE-140 | Growth Inhibition assay | IC50 = 14.6327 μM | SANGER | |||
| SK-PN-DW | Growth Inhibition assay | IC50 = 14.8001 μM | SANGER | |||
| A253 | Growth Inhibition assay | IC50 = 15.0625 μM | SANGER | |||
| CAL-12T | Growth Inhibition assay | IC50 = 15.4662 μM | SANGER | |||
| COLO-679 | Growth Inhibition assay | IC50 = 15.7683 μM | SANGER | |||
| UACC-257 | Growth Inhibition assay | IC50 = 16.1201 μM | SANGER | |||
| U-87-MG | Growth Inhibition assay | IC50 = 16.3523 μM | SANGER | |||
| HCC1806 | Growth Inhibition assay | IC50 = 16.7071 μM | SANGER | |||
| NCI-H2170 | Growth Inhibition assay | IC50 = 17.2448 μM | SANGER | |||
| AGS | Growth Inhibition assay | IC50 = 17.3808 μM | SANGER | |||
| MEL-HO | Growth Inhibition assay | IC50 = 17.7503 μM | SANGER | |||
| SW48 | Growth Inhibition assay | IC50 = 17.7716 μM | SANGER | |||
| HuP-T4 | Growth Inhibition assay | IC50 = 18.0206 μM | SANGER | |||
| NCI-H720 | Growth Inhibition assay | IC50 = 18.1402 μM | SANGER | |||
| RCC10RGB | Growth Inhibition assay | IC50 = 18.1697 μM | SANGER | |||
| HD-MY-Z | Growth Inhibition assay | IC50 = 18.2254 μM | SANGER | |||
| A427 | Growth Inhibition assay | IC50 = 18.5094 μM | SANGER | |||
| HCC2998 | Growth Inhibition assay | IC50 = 18.6051 μM | SANGER | |||
| EPLC-272H | Growth Inhibition assay | IC50 = 19.0434 μM | SANGER | |||
| C32 | Growth Inhibition assay | IC50 = 19.045 μM | SANGER | |||
| UMC-11 | Growth Inhibition assay | IC50 = 19.2123 μM | SANGER | |||
| CaR-1 | Growth Inhibition assay | IC50 = 19.6804 μM | SANGER | |||
| KYSE-410 | Growth Inhibition assay | IC50 = 19.9139 μM | SANGER | |||
| HuCCT1 | Growth Inhibition assay | IC50 = 20.6293 μM | SANGER | |||
| LB996-RCC | Growth Inhibition assay | IC50 = 20.7168 μM | SANGER | |||
| KYSE-70 | Growth Inhibition assay | IC50 = 20.8059 μM | SANGER | |||
| CAL-72 | Growth Inhibition assay | IC50 = 20.915 μM | SANGER | |||
| Capan-2 | Growth Inhibition assay | IC50 = 21.0413 μM | SANGER | |||
| PANC-08-13 | Growth Inhibition assay | IC50 = 21.2515 μM | SANGER | |||
| SBC-1 | Growth Inhibition assay | IC50 = 21.3081 μM | SANGER | |||
| MFM-223 | Growth Inhibition assay | IC50 = 21.3342 μM | SANGER | |||
| BB49-HNC | Growth Inhibition assay | IC50 = 21.5716 μM | SANGER | |||
| SH-4 | Growth Inhibition assay | IC50 = 21.6618 μM | SANGER | |||
| HuO9 | Growth Inhibition assay | IC50 = 21.9825 μM | SANGER | |||
| AM-38 | Growth Inhibition assay | IC50 = 22.0485 μM | SANGER | |||
| A431 | Growth Inhibition assay | IC50 = 23.2119 μM | SANGER | |||
| YAPC | Growth Inhibition assay | IC50 = 23.2651 μM | SANGER | |||
| LU-139 | Growth Inhibition assay | IC50 = 23.4809 μM | SANGER | |||
| HEC-1 | Growth Inhibition assay | IC50 = 23.4937 μM | SANGER | |||
| SCC-25 | Growth Inhibition assay | IC50 = 24.3006 μM | SANGER | |||
| HT-29 | Growth Inhibition assay | IC50 = 24.3823 μM | SANGER | |||
| PC-14 | Growth Inhibition assay | IC50 = 24.6571 μM | SANGER | |||
| Calu-6 | Growth Inhibition assay | IC50 = 25.5071 μM | SANGER | |||
| SJRH30 | Growth Inhibition assay | IC50 = 25.6496 μM | SANGER | |||
| ChaGo-K-1 | Growth Inhibition assay | IC50 = 26.1629 μM | SANGER | |||
| IA-LM | Growth Inhibition assay | IC50 = 26.3645 μM | SANGER | |||
| GP5d | Growth Inhibition assay | IC50 = 26.4491 μM | SANGER | |||
| NCI-H2291 | Growth Inhibition assay | IC50 = 26.6541 μM | SANGER | |||
| BALL-1 | Growth Inhibition assay | IC50 = 26.9397 μM | SANGER | |||
| HCC1954 | Growth Inhibition assay | IC50 = 26.9808 μM | SANGER | |||
| NCI-H2452 | Growth Inhibition assay | IC50 = 27.4163 μM | SANGER | |||
| LU-99A | Growth Inhibition assay | IC50 = 27.5582 μM | SANGER | |||
| NTERA-S-cl-D1 | Growth Inhibition assay | IC50 = 27.7299 μM | SANGER | |||
| PANC-10-05 | Growth Inhibition assay | IC50 = 27.7775 μM | SANGER | |||
| NCI-H2405 | Growth Inhibition assay | IC50 = 27.9387 μM | SANGER | |||
| MDA-MB-415 | Growth Inhibition assay | IC50 = 28.4137 μM | SANGER | |||
| NCI-H2342 | Growth Inhibition assay | IC50 = 28.5281 μM | SANGER | |||
| TGBC24TKB | Growth Inhibition assay | IC50 = 28.7117 μM | SANGER | |||
| LU-134-A | Growth Inhibition assay | IC50 = 28.9261 μM | SANGER | |||
| SCC-4 | Growth Inhibition assay | IC50 = 31.0495 μM | SANGER | |||
| Saos-2 | Growth Inhibition assay | IC50 = 31.9306 μM | SANGER | |||
| RERF-LC-MS | Growth Inhibition assay | IC50 = 32.8231 μM | SANGER | |||
| M14 | Growth Inhibition assay | IC50 = 32.9764 μM | SANGER | |||
| HPAF-II | Growth Inhibition assay | IC50 = 33.5011 μM | SANGER | |||
| NCI-H1755 | Growth Inhibition assay | IC50 = 34.3305 μM | SANGER | |||
| D-392MG | Growth Inhibition assay | IC50 = 35.8674 μM | SANGER | |||
| A704 | Growth Inhibition assay | IC50 = 36.0427 μM | SANGER | |||
| CP50-MEL-B | Growth Inhibition assay | IC50 = 36.1911 μM | SANGER | |||
| EW-18 | Growth Inhibition assay | IC50 = 36.452 μM | SANGER | |||
| WM-115 | Growth Inhibition assay | IC50 = 36.8099 μM | SANGER | |||
| LU-65 | Growth Inhibition assay | IC50 = 37.1417 μM | SANGER | |||
| NCI-H1563 | Growth Inhibition assay | IC50 = 37.2484 μM | SANGER | |||
| DBTRG-05MG | Growth Inhibition assay | IC50 = 38.0691 μM | SANGER | |||
| NCI-H630 | Growth Inhibition assay | IC50 = 38.4714 μM | SANGER | |||
| NCI-H1155 | Growth Inhibition assay | IC50 = 39.242 μM | SANGER | |||
| OVCAR-3 | Growth Inhibition assay | IC50 = 39.9195 μM | SANGER | |||
| OAW-42 | Growth Inhibition assay | IC50 = 40.4258 μM | SANGER | |||
| JVM-2 | Growth Inhibition assay | IC50 = 41.2415 μM | SANGER | |||
| C3A | Growth Inhibition assay | IC50 = 41.3447 μM | SANGER | |||
| HT55 | Growth Inhibition assay | IC50 = 42.2841 μM | SANGER | |||
| OVCAR-4 | Growth Inhibition assay | IC50 = 42.2974 μM | SANGER | |||
| MEG-01 | Growth Inhibition assay | IC50 = 42.4616 μM | SANGER | |||
| NCI-H82 | Growth Inhibition assay | IC50 = 43.9892 μM | SANGER | |||
| JEG-3 | Growth Inhibition assay | IC50 = 44.947 μM | SANGER | |||
| BPH-1 | Growth Inhibition assay | IC50 = 46.3998 μM | SANGER | |||
| MPP-89 | Growth Inhibition assay | IC50 = 47.2898 μM | SANGER | |||
| ALL-PO | Growth Inhibition assay | IC50 = 47.4188 μM | SANGER | |||
| HT | Growth Inhibition assay | IC50 = 47.492 μM | SANGER | |||
| NCI-H2347 | Growth Inhibition assay | IC50 = 48.0715 μM | SANGER | |||
| A2780 | Growth Inhibition assay | IC50 = 49.4228 μM | SANGER | |||
| KARPAS-299 | Growth Inhibition assay | IC50 = 49.5119 μM | SANGER | |||
| NCI-H1651 | Growth Inhibition assay | IC50 = 49.8821 μM | SANGER | |||
| OCI-AML2 | Growth Inhibition assay | IC50 = 50.2084 μM | SANGER | |||
| OCUB-M | Growth Inhibition assay | IC50 = 50.3047 μM | SANGER | |||
| HuH-7 | Growth Inhibition assay | IC50 = 50.5943 μM | SANGER | |||
| RCM-1 | Growth Inhibition assay | IC50 = 50.9133 μM | SANGER | |||
| FTC-133 | Growth Inhibition assay | IC50 = 51.322 μM | SANGER | |||
| PSN1 | Growth Inhibition assay | IC50 = 51.4335 μM | SANGER | |||
| A498 | Growth Inhibition assay | IC50 = 52.0995 μM | SANGER | |||
| SF126 | Growth Inhibition assay | IC50 = 52.6568 μM | SANGER | |||
| UACC-62 | Growth Inhibition assay | IC50 = 55.2224 μM | SANGER | |||
| PANC-03-27 | Growth Inhibition assay | IC50 = 56.6788 μM | SANGER | |||
| NCI-H727 | Growth Inhibition assay | IC50 = 56.8127 μM | SANGER | |||
| SNU-423 | Growth Inhibition assay | IC50 = 57.2859 μM | SANGER | |||
| LB771-HNC | Growth Inhibition assay | IC50 = 57.8405 μM | SANGER | |||
| HCC1395 | Growth Inhibition assay | IC50 = 58.0464 μM | SANGER | |||
| OAW-28 | Growth Inhibition assay | IC50 = 58.2785 μM | SANGER | |||
| NB12 | Growth Inhibition assay | IC50 = 60.6696 μM | SANGER | |||
| DJM-1 | Growth Inhibition assay | IC50 = 60.7331 μM | SANGER | |||
| MDA-MB-157 | Growth Inhibition assay | IC50 = 61.1649 μM | SANGER | |||
| DU-4475 | Growth Inhibition assay | IC50 = 62.5495 μM | SANGER | |||
| RD | Growth Inhibition assay | IC50 = 62.7387 μM | SANGER | |||
| LS-123 | Growth Inhibition assay | IC50 = 63.2618 μM | SANGER | |||
| NCI-H226 | Growth Inhibition assay | IC50 = 64.22 μM | SANGER | |||
| MS-1 | Growth Inhibition assay | IC50 = 64.8358 μM | SANGER | |||
| no-10 | Growth Inhibition assay | IC50 = 65.7473 μM | SANGER | |||
| SW626 | Growth Inhibition assay | IC50 = 65.7579 μM | SANGER | |||
| DMS-273 | Growth Inhibition assay | IC50 = 66.2296 μM | SANGER | |||
| ESS-1 | Growth Inhibition assay | IC50 = 66.5096 μM | SANGER | |||
| TE-9 | Growth Inhibition assay | IC50 = 66.6316 μM | SANGER | |||
| CAS-1 | Growth Inhibition assay | IC50 = 67.7954 μM | SANGER | |||
| 639-V | Growth Inhibition assay | IC50 = 69.4198 μM | SANGER | |||
| GAK | Growth Inhibition assay | IC50 = 70.2031 μM | SANGER | |||
| NCI-H526 | Growth Inhibition assay | IC50 = 71.0913 μM | SANGER | |||
| DoTc2-4510 | Growth Inhibition assay | IC50 = 71.443 μM | SANGER | |||
| 647-V | Growth Inhibition assay | IC50 = 73.2118 μM | SANGER | |||
| OVCAR-8 | Growth Inhibition assay | IC50 = 73.2367 μM | SANGER | |||
| COLO-680N | Growth Inhibition assay | IC50 = 75.2497 μM | SANGER | |||
| HDLM-2 | Growth Inhibition assay | IC50 = 75.7806 μM | SANGER | |||
| TGBC11TKB | Growth Inhibition assay | IC50 = 79.0192 μM | SANGER | |||
| DMS-114 | Growth Inhibition assay | IC50 = 81.9577 μM | SANGER | |||
| CW-2 | Growth Inhibition assay | IC50 = 82.6818 μM | SANGER | |||
| MDA-MB-175-VII | Growth Inhibition assay | IC50 = 85.3135 μM | SANGER | |||
| HT-1376 | Growth Inhibition assay | IC50 = 85.846 μM | SANGER | |||
| SW1417 | Growth Inhibition assay | IC50 = 88.2906 μM | SANGER | |||
| HCE-T | Growth Inhibition assay | IC50 = 91.7205 μM | SANGER | |||
| OE19 | Growth Inhibition assay | IC50 = 92.7944 μM | SANGER | |||
| NCI-N87 | Growth Inhibition assay | IC50 = 92.8881 μM | SANGER | |||
| SNU-449 | Growth Inhibition assay | IC50 = 93.584 μM | SANGER | |||
| NCI-H1092 | Growth Inhibition assay | IC50 = 96.5851 μM | SANGER | |||
| COLO-684 | Growth Inhibition assay | IC50 = 99.0686 μM | SANGER | |||
| HCC1937 | Growth Inhibition assay | IC50 = 99.9315 μM | SANGER | |||
| EFO-21 | Growth Inhibition assay | IC50 = 110.988 μM | SANGER | |||
| ZR-75-30 | Growth Inhibition assay | IC50 = 114.117 μM | SANGER | |||
| HCC1187 | Growth Inhibition assay | IC50 = 114.179 μM | SANGER | |||
| SW684 | Growth Inhibition assay | IC50 = 114.655 μM | SANGER | |||
| AU565 | Growth Inhibition assay | IC50 = 115.892 μM | SANGER | |||
| HCC38 | Growth Inhibition assay | IC50 = 116.559 μM | SANGER | |||
| LK-2 | Growth Inhibition assay | IC50 = 119.652 μM | SANGER | |||
| LB2518-MEL | Growth Inhibition assay | IC50 = 122.428 μM | SANGER | |||
| COLO-320-HSR | Growth Inhibition assay | IC50 = 126.212 μM | SANGER | |||
| HCC1419 | Growth Inhibition assay | IC50 = 129.227 μM | SANGER | |||
| NCI-H2228 | Growth Inhibition assay | IC50 = 129.321 μM | SANGER | |||
| NCI-H2052 | Growth Inhibition assay | IC50 = 130.358 μM | SANGER | |||
| HCC2157 | Growth Inhibition assay | IC50 = 133.973 μM | SANGER | |||
| HCC1569 | Growth Inhibition assay | IC50 = 135.05 μM | SANGER | |||
| HuO-3N1 | Growth Inhibition assay | IC50 = 135.366 μM | SANGER | |||
| MZ7-mel | Growth Inhibition assay | IC50 = 145.604 μM | SANGER | |||
| SW756 | Growth Inhibition assay | IC50 = 147.143 μM | SANGER | |||
| NCI-H1304 | Growth Inhibition assay | IC50 = 149.222 μM | SANGER | |||
| LN-405 | Growth Inhibition assay | IC50 = 149.732 μM | SANGER | |||
| BT-474 | Growth Inhibition assay | IC50 = 150.969 μM | SANGER | |||
| LS-411N | Growth Inhibition assay | IC50 = 152.319 μM | SANGER | |||
| ATN-1 | Growth Inhibition assay | IC50 = 152.458 μM | SANGER | |||
| SNU-C2B | Growth Inhibition assay | IC50 = 153.444 μM | SANGER | |||
| KYSE-270 | Growth Inhibition assay | IC50 = 155.75 μM | SANGER | |||
| NCI-H1395 | Growth Inhibition assay | IC50 = 156.493 μM | SANGER | |||
| EKVX | Growth Inhibition assay | IC50 = 156.981 μM | SANGER | |||
| HCC70 | Growth Inhibition assay | IC50 = 157.989 μM | SANGER | |||
| NCI-H522 | Growth Inhibition assay | IC50 = 161.368 μM | SANGER | |||
| Ca-Ski | Growth Inhibition assay | IC50 = 161.86 μM | SANGER | |||
| SW1116 | Growth Inhibition assay | IC50 = 163.382 μM | SANGER | |||
| 8-MG-BA | Growth Inhibition assay | IC50 = 165.797 μM | SANGER | |||
| NCI-H1048 | Growth Inhibition assay | IC50 = 172.374 μM | SANGER | |||
| RH-18 | Growth Inhibition assay | IC50 = 172.601 μM | SANGER | |||
| LU-135 | Growth Inhibition assay | IC50 = 173.259 μM | SANGER | |||
| SW948 | Growth Inhibition assay | IC50 = 174.6 μM | SANGER | |||
| LS-1034 | Growth Inhibition assay | IC50 = 183.742 μM | SANGER | |||
| SCH | Growth Inhibition assay | IC50 = 187.022 μM | SANGER | |||
| KP-N-YN | Growth Inhibition assay | IC50 = 192.971 μM | SANGER | |||
| NCI-H69 | Growth Inhibition assay | IC50 = 210.925 μM | SANGER | |||
| SBC-5 | Growth Inhibition assay | IC50 = 211.162 μM | SANGER | |||
| MFE-280 | Growth Inhibition assay | IC50 = 212.067 μM | SANGER | |||
| MC116 | Growth Inhibition assay | IC50 = 212.736 μM | SANGER | |||
| BT-20 | Growth Inhibition assay | IC50 = 216.38 μM | SANGER | |||
| NCI-H1993 | Growth Inhibition assay | IC50 = 217.295 μM | SANGER | |||
| Calu-3 | Growth Inhibition assay | IC50 = 217.37 μM | SANGER | |||
| GCIY | Growth Inhibition assay | IC50 = 221.332 μM | SANGER | |||
| HT-3 | Growth Inhibition assay | IC50 = 222.173 μM | SANGER | |||
| MC-IXC | Growth Inhibition assay | IC50 = 227.215 μM | SANGER | |||
| COR-L88 | Growth Inhibition assay | IC50 = 234.259 μM | SANGER | |||
| SK-MEL-1 | Growth Inhibition assay | IC50 = 235.59 μM | SANGER | |||
| MDA-MB-453 | Growth Inhibition assay | IC50 = 236.33 μM | SANGER | |||
| SiHa | Growth Inhibition assay | IC50 = 247.22 μM | SANGER | |||
| C8166 | Growth Inhibition assay | IC50 = 251.341 μM | SANGER | |||
| SKG-IIIa | Growth Inhibition assay | IC50 = 251.504 μM | SANGER | |||
| HT-1197 | Growth Inhibition assay | IC50 = 268.492 μM | SANGER | |||
| no-11 | Growth Inhibition assay | IC50 = 291.357 μM | SANGER | |||
| ME-180 | Growth Inhibition assay | IC50 = 296.912 μM | SANGER | |||
| NY | Growth Inhibition assay | IC50 = 320.632 μM | SANGER | |||
| C-33-A | Growth Inhibition assay | IC50 = 325.06 μM | SANGER | |||
| NCI-H2029 | Growth Inhibition assay | IC50 = 338.305 μM | SANGER | |||
| IST-SL1 | Growth Inhibition assay | IC50 = 342.105 μM | SANGER | |||
| KLE | Growth Inhibition assay | IC50 = 347.29 μM | SANGER | |||
| SF539 | Growth Inhibition assay | IC50 = 348.01 μM | SANGER | |||
| 5637 | Growth Inhibition assay | IC50 = 360.37 μM | SANGER | |||
| COLO-824 | Growth Inhibition assay | IC50 = 363.58 μM | SANGER | |||
| NCI-H810 | Growth Inhibition assay | IC50 = 363.938 μM | SANGER | |||
| JAR | Growth Inhibition assay | IC50 = 365.01 μM | SANGER | |||
| L-428 | Growth Inhibition assay | IC50 = 369.277 μM | SANGER | |||
| COLO-668 | Growth Inhibition assay | IC50 = 387.033 μM | SANGER | |||
| GI-1 | Growth Inhibition assay | IC50 = 398.59 μM | SANGER | |||
| NCI-H446 | Growth Inhibition assay | IC50 = 399.497 μM | SANGER | |||
| CCRF-CEM | Growth Inhibition assay | IC50 = 403.587 μM | SANGER | |||
| T84 | Growth Inhibition assay | IC50 = 403.686 μM | SANGER | |||
| K-562 | Growth Inhibition assay | IC50 = 432.947 μM | SANGER | |||
| OMC-1 | Growth Inhibition assay | IC50 = 433.814 μM | SANGER | |||
| LB831-BLC | Growth Inhibition assay | IC50 = 434.556 μM | SANGER | |||
| BT-549 | Growth Inhibition assay | IC50 = 435.102 μM | SANGER | |||
| MKN7 | Growth Inhibition assay | IC50 = 439.822 μM | SANGER | |||
| SW1783 | Growth Inhibition assay | IC50 = 449.251 μM | SANGER | |||
| SNB75 | Growth Inhibition assay | IC50 = 486.478 μM | SANGER | |||
| M059J | Growth Inhibition assay | IC50 = 492.923 μM | SANGER | |||
| KURAMOCHI | Growth Inhibition assay | IC50 = 498.612 μM | SANGER | |||
| TE-1 | Growth Inhibition assay | IC50 = 502.729 μM | SANGER | |||
| NCI-H596 | Growth Inhibition assay | IC50 = 530.805 μM | SANGER | |||
| PFSK-1 | Growth Inhibition assay | IC50 = 532.941 μM | SANGER | |||
| MOLM13 | Function assay | 24 hrs | Inhibition of CDK4 in human MOLM13 cells assessed as inhibition of Rb phosphorylation at Ser780 after 24 hrs, IC50 = 0.011 μM. | 24641103 | ||
| COLO205 | Antiproliferative assay | 72 hrs | Antiproliferative activity against Rb-positive human COLO205 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis, IC50 = 0.036 μM. | 24641103 | ||
| MOLM13 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MOLM13 cells harboring FLT3 ITD mutant assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis, IC50 = 0.096 μM. | 24641103 | ||
| MOLM13 | Antiproliferative assay | 72 hrs | Antiproliferative activity against sorafenib-resistant human MOLM13 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis, IC50 = 0.096 μM. | 24641103 | ||
| U937 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human U937 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis, IC50 = 0.14 μM. | 24641103 | ||
| insect cell | Function assay | 2 mins | Inhibition of CDK6/cyclin D2 (unknown origin) expressed in baculovirus infected insect cells using GST-fused pRb (792 to 928) as substrate preincubated for 2 mins followed by [gamma-32P]-ATP addition measured after 15 mins by beta plate counting analysis, IC50 = 0.009 μM. | 26115571 | ||
| insect cell | Function assay | 2 mins | Inhibition of CDK6/cyclin D2 (unknown origin) expressed in baculovirus infected insect cells using GST-fused pRb (792 to 928) as substrate preincubated for 2 mins followed by [gamma-32P]-ATP addition measured after 15 mins by beta plate counting analysis, IC50 = 0.009 μM. | 26115571 | ||
| insect cell | Function assay | 2 mins | Inhibition of CDK4/cyclin D1 (unknown origin) expressed in baculovirus infected insect cells using GST-fused pRb (792 to 928) as substrate preincubated for 2 mins followed by [gamma-32P]-ATP addition measured after 15 mins by beta plate counting analysis, IC50 = 0.011 μM. | 26115571 | ||
| insect cell | Function assay | 2 mins | Inhibition of CDK4/cyclin D1 (unknown origin) expressed in baculovirus infected insect cells using GST-fused pRb (792 to 928) as substrate preincubated for 2 mins followed by [gamma-32P]-ATP addition measured after 15 mins by beta plate counting analysis, IC50 = 0.011 μM. | 26115571 | ||
| MDA-MB-435 | Antiproliferative assay | 24 hrs | Antiproliferative activity against Rb-positive human MDA-MB-435 cells assessed as inhibition of [14C]-thymidine incorporation into DNA preincubated for 24 hrs followed by [14C]-thymidine addition measured after 72 hrs by beta plate counting analysis, IC50 = 0.16 μM. | 26115571 | ||
| sf9 | Function assay | Inhibition of CDK2/Cyclin E (unknown origin) expressed in sf9 cells using histone H1 as substrate in presence of [gamma33P]-ATP, IC50 = 9.2 μM. | 26851505 | |||
| sf9 | Function assay | Inhibition of CDK2/Cyclin E (unknown origin) expressed in sf9 cells using histone H1 as substrate in presence of [gamma33P]-ATP, IC50 = 9.2 μM. | 26851505 | |||
| insect cell | Function assay | 2 mins | Inhibition of CDK4/cyclin D1 (unknown origin) expressed in baculovirus infected insect cells using GST-tagged pRB (792 to 928 residues) as substrate preincubated for 2 mins followed by [gamma32P]ATP addition measured after 15 mins by beta counting method, IC50 = 0.011 μM. | 27171036 | ||
| insect cell | Function assay | 2 mins | Inhibition of CDK4/cyclin D1 (unknown origin) expressed in baculovirus infected insect cells using GST-tagged pRB (792 to 928 residues) as substrate preincubated for 2 mins followed by [gamma32P]ATP addition measured after 15 mins by beta counting method, IC50 = 0.011 μM. | 27171036 | ||
| insect cell | Function assay | 2 mins | Inhibition of CDK6/cyclin D2 (unknown origin) expressed in baculovirus infected insect cells using GST-tagged pRB (792 to 928 residues) as substrate preincubated for 2 mins followed by [gamma32P]ATP addition measured after 15 mins by beta counting method, IC50 = 0.015 μM. | 27171036 | ||
| insect cell | Function assay | 2 mins | Inhibition of CDK6/cyclin D2 (unknown origin) expressed in baculovirus infected insect cells using GST-tagged pRB (792 to 928 residues) as substrate preincubated for 2 mins followed by [gamma32P]ATP addition measured after 15 mins by beta counting method, IC50 = 0.015 μM. | 27171036 | ||
| MDA-MB-453 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay, IC50 = 0.137 μM. | 27448913 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay, IC50 = 0.24 μM. | 27448913 | ||
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay, IC50 = 0.58 μM. | 27448913 | ||
| MCF7 | Antitumor assay | 100 mg/kg/day | 14 days | Antitumor activity against human estrogen-independent human MCF7 cells xenografted in RNU rat assessed as tumor growth inhibition at 100 mg/kg/day, ig administered for 14 days measured on day 15 | 27448913 | |
| A2780 | Growth inhibition assay | 72 hrs | Growth inhibition of human A2780 cells after 72 hrs by resazurin or MTT assay, GI50 = 0.032 μM. | 28156111 | ||
| MV4-11 | Growth inhibition assay | 72 hrs | Growth inhibition of human MV4-11 cells after 72 hrs by resazurin assay, GI50 = 0.05 μM. | 28156111 | ||
| MOLM13 | Growth inhibition assay | 72 hrs | Growth inhibition of human MOLM13 cells after 72 hrs by resazurin or MTT assay, GI50 = 0.062 μM. | 28156111 | ||
| NB4 | Growth inhibition assay | 72 hrs | Growth inhibition of human NB4 cells after 72 hrs by resazurin or MTT assay, GI50 = 0.066 μM. | 28156111 | ||
| PC3 | Growth inhibition assay | 72 hrs | Growth inhibition of human PC3 cells after 72 hrs by resazurin or MTT assay, GI50 = 0.071 μM. | 28156111 | ||
| MDA-MB-453 | Growth inhibition assay | 72 hrs | Growth inhibition of human MDA-MB-453 cells after 72 hrs by MTT assay, GI50 = 0.326 μM. | 28156111 | ||
| MCF7 | Growth inhibition assay | 72 hrs | Growth inhibition of human MCF7 cells after 72 hrs by resazurin or MTT assay, GI50 = 0.557 μM. | 28156111 | ||
| M229 | Growth inhibition assay | 72 hrs | Growth inhibition of human M229 cells after 72 hrs by resazurin or MTT assay, GI50 = 1.22 μM. | 28156111 | ||
| M238 | Growth inhibition assay | 72 hrs | Growth inhibition of human M238 cells after 72 hrs by resazurin or MTT assay, GI50 = 1.97 μM. | 28156111 | ||
| M249 | Growth inhibition assay | 72 hrs | Growth inhibition of human M249 cells after 72 hrs by resazurin or MTT assay, GI50 = 1.99 μM. | 28156111 | ||
| M249R | Growth inhibition assay | 72 hrs | Growth inhibition of human M249R cells after 72 hrs by resazurin or MTT assay, GI50 = 2.96 μM. | 28156111 | ||
| C4-2B | Growth inhibition assay | 72 hrs | Growth inhibition of human C4-2B cells after 72 hrs by resazurin or MTT assay, GI50 = 4.15 μM. | 28156111 | ||
| DU145 | Growth inhibition assay | 72 hrs | Growth inhibition of human DU145 cells after 72 hrs by resazurin or MTT assay, GI50 = 5.792 μM. | 28156111 | ||
| MDA-MB-468 | Growth inhibition assay | 72 hrs | Growth inhibition of human MDA-MB-468 cells after 72 hrs by resazurin or MTT assay, GI50 = 5.96 μM. | 28156111 | ||
| BPH1 | Growth inhibition assay | 72 hrs | Growth inhibition of nontransformed human BPH1 cells after 72 hrs by resazurin or MTT assay, GI50 = 7.442 μM. | 28156111 | ||
| K562 | Cytotoxicity assay | 96 hrs | Cytotoxicity against human K562 cells after 96 hrs by Cell-Titer Blue assay, IC50 = 2 μM. | 24417566 | ||
| DU145 | Cytotoxicity assay | 96 hrs | Cytotoxicity against human DU145 cells after 96 hrs by Cell-Titer Blue assay, IC50 = 7.5 μM. | 24417566 | ||
| MDA-MB-231 | Cell cycle arrest assay | 0.5 to 1 uM | 24 hrs | Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G1 phase at 0.5 to 1 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis | 24417566 | |
| MCF7 | Cell cycle arrest assay | 0.5 to 1 uM | 24 hrs | Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 0.5 to 1 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis | 24417566 | |
| MDA-MB-231 | Function assay | 0.5 to 5 uM | 24 hrs | Inhibition of recombinant CDK4/cyclinD1 in human MDA-MB-231 cells assessed as inhibition of retinoblastoma phosphorylation at Ser780 at 0.5 to 5 uM after 24 hrs by Western blotting analysis | 24417566 | |
| MDA-MB-231 | Function assay | 0.5 to 5 uM | 24 hrs | Inhibition of recombinant CDK4/cyclinD1 in human MDA-MB-231 cells assessed as inhibition of retinoblastoma phosphorylation at Ser780 at 0.5 to 5 uM after 24 hrs by Western blotting analysis | 24417566 | |
| MCF7 | Function assay | 0.5 to 5 uM | 24 hrs | Inhibition of recombinant CDK4/cyclinD1 in human MCF7 cells assessed as inhibition of retinoblastoma phosphorylation at Ser780 at 0.5 to 5 uM after 24 hrs by Western blotting analysis | 24417566 | |
| MCF7 | Function assay | 0.5 to 5 uM | 24 hrs | Inhibition of recombinant CDK4/cyclinD1 in human MCF7 cells assessed as inhibition of retinoblastoma phosphorylation at Ser780 at 0.5 to 5 uM after 24 hrs by Western blotting analysis | 24417566 | |
| MV4-11 | Function assay | 12 to 24 hrs | Inhibition of CDK4/6 in human MV4-11 cells assessed as reduction in Rb phosphorylation at Ser780 at GI50 after 12 to 24 hrs by Western blot analysis | 28156111 | ||
| MV4-11 | Function assay | 12 to 24 hrs | Inhibition of CDK4/6 in human MV4-11 cells assessed as reduction in Rb phosphorylation at Ser780 at GI50 after 12 to 24 hrs by Western blot analysis | 28156111 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| Cliquez pour voir plus de données expérimentales sur la lignée cellulaire | ||||||
| Poids moléculaire | 573.66 | Formule | C24H29N7O2.C2H6O4S |
Stockage (À compter de la date de réception) | |
|---|---|---|---|---|---|
| N° CAS | 827022-33-3 | Télécharger le SDF | Stockage des solutions mères |
|
|
| Synonymes | PD0332991 Isethionate | Smiles | CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.C(CS(=O)(=O)O)O | ||
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant l'expérience)
Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter d'abord s'il n'y a pas de formulation in vivo dans la section Solubilité.)
Résultats du calcul :
Concentration de travail : mg/ml;
Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter d'abord si la concentration dépasse la solubilité du DMSO du lot de médicament. )
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH2O, mélanger et clarifier.
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.
Note : 1. Veuillez vous assurer que le liquide est clair avant d'ajouter le solvant suivant.
2. Assurez-vous d'ajouter le(s) solvant(s) dans l'ordre. Vous devez vous assurer que la solution obtenue, lors de l'ajout précédent, est une solution claire avant de procéder à l'ajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.
| Caractéristiques |
The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
|
|---|---|
| Targets/IC50/Ki |
CDK4/CyclinD3
(Cell-free assay) 9 nM
CDK4/CyclinD1
(Cell-free assay) 11 nM
CDK6/CyclinD2
(Cell-free assay) 15 nM
|
| In vitro |
PD-0332991 (Palbociclib) Isethionate présente une sélectivité absolue pour CDK4/6 avec peu ou pas d'activité contre d'autres CDK. PD-0332991 (Palbociclib) Isethionate est efficace pour réduire la phosphorylation de Rb aux niveaux de Ser780 et Ser795 dans les cellules de carcinome mammaire MDA-MB-435 avec des IC50 de 66 nM et 63 nM, respectivement. PD-0332991 (Palbociclib) Isethionate est un puissant inhibiteur de la croissance cellulaire et supprime la réplication de l'ADN en empêchant les cellules d'entrer en phase S. PD-0332991 (Palbociclib) Isethionate inhibe l'incorporation de thymidine dans l'ADN des carcinomes humains du sein Rb-positifs (tels que MDA-MB-435, MCF-7), du côlon (H1299) et du poumon (Colo-205) ainsi que des leucémies humaines (CRRF-CEM et K562), avec des valeurs d'IC50 allant de 0,04 à 0,17 μM. PD-0332991 (Palbociclib) Isethionate augmente significativement le pourcentage de MDA-MB-453 en période G1. PD-0332991 (Palbociclib) Isethionate inhibe la phosphorylation de Rb dans les cellules de myélome de la moelle osseuse primaire CD138+ en cycle, les cellules B primaires non transformées, et les lignées cellulaires HMCL MM1.S et CAG avec des IC50 de <0,1 μM, 0,05 μM et 60-70 nM, respectivement. Le traitement par PD-0332991 (Palbociclib) Isethionate induit également un arrêt en G1 des cellules de myélome de la moelle osseuse primaire CD138+ et des cellules B primaires non transformées. PD-0332991 (Palbociclib) Isethionate induit un arrêt en G1 dans MM1.S avec une IC50 de ~0,05 μM. PD-0332991 (Palbociclib) Isethionate inhibe préférentiellement la prolifération des lignées cellulaires de cancer du sein humain luminales récepteurs d'œstrogènes positifs (y compris HER2 positifs). PD-0332991 (Palbociclib) Isethionate augmente l'expression génique de pRb et de la cycline D1 et diminue l'expression génique de CDKN2A (p16) dans la plupart des lignées sensibles. PD-0332991 (Palbociclib) Isethionate améliore la sensibilité au tamoxifène dans les lignées cellulaires présentant une résistance conditionnée au blocage des récepteurs d'œstrogènes (ER).
|
| Essai kinase |
Dosages de l'activité CDK
|
|
Les dosages CDK pour les déterminations de la CI50 et l'évaluation cinétique sont effectués dans des plaques filtrantes de 96 puits. Tous les complexes CDK-cycline kinase sont exprimés dans des cellules d'insectes par infection au baculovirus et purifiés. Le substrat pour les dosages est un fragment (acides aminés 792-928) de pRb fusionné au GST (GST•RB-Cterm). Le volume total de réaction est de 0,1 mL contenant une concentration finale de 20 mM Tris-HCl, pH 7,4, 50 mM NaCl, 1 mM dithiothréitol, 10 mM MgCl2, 25 μM d'ATP (pour CDK4-cycline D1, CDK6-cycline D2 et CDK6-cycline D3) contenant 0,25 μCi de [γ-32P]ATP, 20 ng d'enzyme, 1 μg de GST•RB-Cterm et des dilutions appropriées d'inhibiteur. Tous les composants, à l'exception du [γ-32P]ATP, sont ajoutés aux puits et placés sur un mélangeur de plaques pendant 2 minutes. La réaction est démarrée par l'ajout de [γ-32P]ATP et incubée à 25 °C pendant 15 minutes. La réaction est terminée par l'ajout de 0,1 mL d'acide trichloroacétique à 20 %, et la plaque est maintenue à 4 °C pendant au moins 1 heure pour permettre la précipitation du substrat. Les puits sont ensuite lavés cinq fois avec 0,2 mL d'acide trichloroacétique à 10 %, et l'incorporation radioactive est déterminée à l'aide d'un compteur de plaques β.
|
|
| In vivo |
PD-0332991 (Palbociclib) Isethionate (150 mg/kg) produit une régression rapide des xénogreffes de carcinome du côlon Colo-205 et un retard de croissance tumorale correspondant. PD-0332991 (Palbociclib) Isethionate (150 mg/kg) induit une stase tumorale complète et la mort cellulaire dans le carcinome mammaire MDA-MB-435. PD-0332991 (Palbociclib) Isethionate (150 mg/kg) induit également une régression tumorale significative chez les souris porteuses de xénogreffes de glioblastome SF-295, ainsi que dans les modèles de tumeurs mammaires ZR-75-1 et prostatiques PC-3 (suppression complète de la croissance tumorale). PD-0332991 (Palbociclib) Isethionate (150 mg/kg) supprime la phosphorylation de Rb Ser780 dans le carcinome mammaire MDA-MB-435 sur une période complète de 24 heures. PD-0332991 (Palbociclib) Isethionate (150 mg/kg) régule négativement l'expression de quatre gènes régulés par E2F : CDC2, CCNE2, TK1 et TOP2A dans les xénogreffes de carcinome Colo-205. PD-0332991 (Palbociclib) Isethionate inhibe également rapidement la croissance tumorale du myélome.
|
Références |
|
| Méthodes | Biomarqueurs | Images | PMID |
|---|---|---|---|
| Western blot | RB1 (pT821) / RB1 (pS780) pAMPKα(T172) / AMPKα pULK1(S317) / ULK1 c-Jun / p-c-Jun / NFκB(p50) p38 / p-P38 / JNK / p-JNK |
|
30300583 |
| Growth inhibition assay | Cell viability IC50 |
|
28453226 |
| Immunofluorescence | γH2AX(Ser139) LC3B |
|
29669860 |
| ELISA | PGE2 |
|
26540629 |
(données du https://clinicaltrials.gov, mis à jour le 2024-05-22)
| Numéro NCT | Recrutement | Conditions | Promoteur/Collaborateurs | Date de début | Phases |
|---|---|---|---|---|---|
| NCT05665361 | Recruiting | Advanced Clear Cell Renal Carcinoma (Ccrcc)|Papillary Renal Cell Carcinoma (Prcc) |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
April 24 2024 | Phase 1|Phase 2 |
| NCT06307457 | Completed | Breast Cancer |
Pfizer |
March 11 2024 | -- |
| NCT05709158 | Not yet recruiting | Breast Cancer |
Pfizer |
March 1 2024 | -- |
| NCT05912933 | Not yet recruiting | Breast Cancer |
Pfizer |
March 1 2024 | -- |
Question 1:
What is the best vehicle for it for in vitro and in vivo?
Réponse :
It can be used with water for vitro use and saline for vivo use.